AoPcasts: Bringing you the latest in medical research

Introducing AoPcasts

March 11, 2021 Association of Physicians Season 1
Introducing AoPcasts
AoPcasts: Bringing you the latest in medical research
More Info
AoPcasts: Bringing you the latest in medical research
Introducing AoPcasts
Mar 11, 2021 Season 1
Association of Physicians

Welcome to the Association of  Physicians (AoP) podcast series AoPcasts: Bringing you the latest in medical research.

The AoPcasts is a fascinating series of podcasts bringing cutting edge medical research to new audiences.  Produced by the AoP and hosted by science broadcaster Vivienne Parry, the series will explore some of the major themes debated at the annual AoP meeting.  

The first AoPcast brings together Rino Rappuoli, Chief Scientist of the vaccines division of GSK and Fellow both of the Royal Society and the US National Academy of Sciences, and Ellie Barnes, Professor of Experimental Medicine at the University of Oxford, globally celebrated for her work on hepatitis vaccines.

Visit our website for further information and to register for our annual meeting taking place on the 15th - 16th March 2021. 

You can follow us on Twitter and LinkedIn 



Show Notes

Welcome to the Association of  Physicians (AoP) podcast series AoPcasts: Bringing you the latest in medical research.

The AoPcasts is a fascinating series of podcasts bringing cutting edge medical research to new audiences.  Produced by the AoP and hosted by science broadcaster Vivienne Parry, the series will explore some of the major themes debated at the annual AoP meeting.  

The first AoPcast brings together Rino Rappuoli, Chief Scientist of the vaccines division of GSK and Fellow both of the Royal Society and the US National Academy of Sciences, and Ellie Barnes, Professor of Experimental Medicine at the University of Oxford, globally celebrated for her work on hepatitis vaccines.

Visit our website for further information and to register for our annual meeting taking place on the 15th - 16th March 2021. 

You can follow us on Twitter and LinkedIn